Ineficácia do allopurinol em pacientes na fase aguda da doença de Chagas

Lauria-Pires, Liana; Castro, Cleudson; Emanuel, Antônio; Prata, Áluízio

doi:10.1590/s0037-86821988000200011

Cited by 15 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data are similar to another study on chronic phase patients, 10 in parallel to our study, and also to a study on acute phase patients, 11 but differs from those referred by oth-ers. 4,5,12 The drug schedule and doses were similar or even higher than those used by these investigators.…”

supporting

confidence: 91%

Specific Treatment for Trypanosoma Cruzi: Lack of Efficacy of Allopurinol in the Human Chronic Phase of Chagas Disease

Luquetti¹,

Rassi²,

Rassi³

et al. 2007

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Thirty-five individuals from endemic areas of Central Brazil (age range, 18-64 years; 19 women) in the chronic phase of Chagas disease, with positive serology and presence of circulating parasites detected by one or more recent positive xenodiagnosis, were selected for this study. Allopurinol (900 mg/d) or placebo was administered in a double-blind clinical trial for 60 days. After codes were broken, 23 had been allocated to the intervention group and 12 to the placebo group. Side effects were observed in 11 patients in the intervention group and in 1 in the placebo group. Seventeen patients in the intervention group and 10 in the placebo group completed the trial. Follow-up was performed by monthly xenodiagnosis and serologic tests every 3 months during the first year and at the end of the trial. Xenodiagnosis remained positive in all 17 of the treated group and in all 10 of the placebo group. Serologic tests were persistently positive in both groups after treatment. We concluded that, at the doses used, allopurinol was not effective to clear, in our region, Trypanosoma cruzi from peripheral blood of infected individuals.

show abstract

supporting

confidence: 91%

Specific Treatment for Trypanosoma Cruzi: Lack of Efficacy of Allopurinol in the Human Chronic Phase of Chagas Disease

Luquetti¹,

Rassi²,

Rassi³

et al. 2007

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…In the treatment of six acute phase patients, allopurinol was ineffective, with maintenance of positive xenodiagnosis and serology (Lauria-Pires et al 1988). In a study, with chronic patients, Galleano et al (1990) treated two groups of patients with 600 and 900 mg/kg/day of allopurinol for 60 days, compared with other two treated with Nif and Bz.…”

Section: Allopurinolmentioning

confidence: 99%

A Critical Review on Chagas Disease Chemotherapy

Coura¹,

Castro

2002

Mem. Inst. Oswaldo Cruz

816

427

View full text Add to dashboard Cite

“…After the introduction of nifurtimox and benznidazole, few compounds were assayed in chagasic patients. The results obtained with allopurinol (ALLO) [4-hydroxypyrazolo (3,4-d) pyrimidine HPP] in experimental animals and the knowledge about its mode of action led to clinical assays for the treatment of Chagas disease (Lauria-Pires et al 1988, Galleano et al 1990.…”

Section: Limitations For the Use Of Specific Therapy In Chagas Diseasementioning

confidence: 99%

Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations

Britto¹

2009

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Ineficácia do allopurinol em pacientes na fase aguda da doença de Chagas

Cited by 15 publications

References 0 publications

Specific Treatment for Trypanosoma Cruzi: Lack of Efficacy of Allopurinol in the Human Chronic Phase of Chagas Disease

Specific Treatment for Trypanosoma Cruzi: Lack of Efficacy of Allopurinol in the Human Chronic Phase of Chagas Disease

A Critical Review on Chagas Disease Chemotherapy

Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations

Contact Info

Product

Resources

About